Edition:
United Kingdom

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

77.37USD
21 Sep 2018
Change (% chg)

$-0.32 (-0.41%)
Prev Close
$77.69
Open
$77.85
Day's High
$77.90
Day's Low
$77.32
Volume
2,238,380
Avg. Vol
713,879
52-wk High
$78.36
52-wk Low
$60.78

Latest Key Developments (Source: Significant Developments)

Baxter Announces U.S. FDA Clearance Of New Bone Graft Substitute, Actifuse Flow
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA CLEARANCE OF NEW BONE GRAFT SUBSTITUTE, ACTIFUSE FLOW.BAXTER INTERNATIONAL INC - EXPECTS ACTIFUSE FLOW TO BE AVAILABLE TO U.S. CUSTOMERS BY YEAR-END.  Full Article

Baxter International Files For Potential Mixed Shelf Offering Size Not Disclosed
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED.  Full Article

Syngene International Expands Collaboration With Baxter Healthcare Corp
Monday, 23 Jul 2018 

July 23 (Reuters) - Syngene International Ltd ::SAYS EXPANDED SCOPE OF ITS RESEARCH AND DEVELOPMENT COLLABORATION WITH BAXTER HEALTHCARE CORPORATION.AS PART OF EXPANSION, SYNGENE WILL SET UP ADDITIONAL INFRASTRUCTURE AT DEDICATED BAXTER GLOBAL RESEARCH CENTER (BGRC).AS PART OF EXPANSION, SYNGENE WILL INCREASE THE SIZE OF ITS SCIENTIFIC TEAM WORKING ON BAXTER PROJECTS .DURATION OF THE AGREEMENT HAS ALSO BEEN EXTENDED UNTIL 2024 .  Full Article

Baxter International Says FDA Released Copy Of A Warning Letter Regarding Co's Ahmedabad Facilities
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Baxter International Inc ::BAXTER INTERNATIONAL SAYS ON JULY 17, FDA RELEASED COPY OF WARNING LETTER REGARDING FDA'S JULY 2017 INSPECTION OF CO'S NEWLY ACQUIRED FACILITIES IN AHMEDABAD.BAXTER INTERNATIONAL - COMING OUT OF 2017 INSPECTION, CO DID NOT INCLUDE ANY 2018 REVENUE FOR NEW CLARIS PRODUCT LAUNCHES IN U.S. IN 2018 FINANCIAL GUIDANCE.BAXTER INTERNATIONAL - RECEIPT OF CLARIS WARNING LETTER DOES NOT CAUSE CO TO CHANGE ITS LONG RANGE FINANCIAL GUIDANCE ISSUED IN MAY 2018 AT THIS TIME.BAXTER INTERNATIONAL INC - RECEIPT OF CLARIS WARNING LETTER DOES NOT CAUSE CO TO MAKE CHANGES TO LONG RANGE FINANCIAL GUIDANCE ISSUED IN MAY 2018.BAXTER INTERNATIONAL INC - EVALUATING OTHER POTENTIAL LOCATIONS, INCLUDING CONTRACT MANUFACTURING ORGANIZATIONS.BAXTER INTERNATIONAL INC - EVALUATING OTHER POTENTIAL LOCATIONS TO SUPPORT PRODUCTION OF NEW PRODUCTS FOR DISTRIBUTION IN U.S..BAXTER INTERNATIONAL INC - EXPECTS REGULATORY MEETING WITH FDA TO OCCUR IN 2018, WITH A REINSPECTION OF FORMER CLARIS INJECTABLES FACILITY TO FOLLOW.BAXTER INTERNATIONAL - EVALUATION ALSO TO MITIGATE RISK OF DELAY IN ABILITY TO REMEDIATE CLARIS INJECTABLES FACILITIES TO FDA'S SATISFACTION BEYOND H1 2020.BAXTER INTERNATIONAL - EVALUATING OTHER LOCATIONS THAT COULD ALSO BE USED TO SUPPORT PRODUCTION OF ANY PENDING PRODUCT APPROVALS.  Full Article

Baxter Declares Dividend And Announces Quarterly Dividend Increase
Tuesday, 8 May 2018 

May 8 (Reuters) - Baxter International Inc ::BAXTER DECLARES DIVIDEND AND ANNOUNCES QUARTERLY DIVIDEND INCREASE.BAXTER INTERNATIONAL INC - ANNOUNCED AN APPROXIMATELY 19% INCREASE IN COMPANY'S QUARTERLY DIVIDEND RATE.BAXTER INTERNATIONAL INC - ANNOUNCED AN APPROXIMATELY 19% INCREASE IN COMPANY'S QUARTERLY DIVIDEND RATE.BAXTER INTERNATIONAL INC - 19 PERCENT RATE INCREASE MADE IN CONNECTION WITH DECLARATION OF A QUARTERLY CASH DIVIDEND OF $0.19 PER SHARE OF COMMON STOCK.  Full Article

Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN.BAXTER INTERNATIONAL SAYS U.S. FDA APPROVED BIVALIRUDIN IN 0.9 PERCENT SODIUM CHLORIDE INJECTION.BAXTER INTERNATIONAL INC - BIVALIRUDIN IS EXPECTED TO LAUNCH IN UNITED STATES IN EARLY 2018.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS.BAXTER INTERNATIONAL - TO ACQUIRE RECOTHROM AND PREVELEAK FOR UPFRONT PAYMENT OF ABOUT $153 MILLION AND POTENTIAL CONTINGENT PAYMENTS IN FUTURE.BAXTER INTERNATIONAL - UPON CLOSING, DEAL EXPECTED TO BE MODESTLY ACCRETIVE TO BAXTER'S 2018 ADJUSTED EPS & INCREASINGLY ACCRETIVE THEREAFTER.BAXTER INTERNATIONAL - ‍PROPOSED DEAL INCLUDES TWO HEMOSTAT & SEALANT PRODUCTS, INCLUDING STAND-ALONE RECOMBINANT THROMBIN, SURGICAL SEALANT​.  Full Article

Baxter sees Q4 revenue to be negatively impacted by about $70 mln due to temporary manufacturing disruptions resulting from Hurricane Maria​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Baxter International Inc :Baxter reports third-quarter 2017 results and updates financial outlook for full-year 2017.Q3 GAAP earnings per share $0.45 from continuing operations.Q3 revenue $2.7 billion versus I/B/E/S view $2.66 billion.Q3 earnings per share view $0.59 -- Thomson Reuters I/B/E/S.Sees Q4 earnings per share $0.56 to $0.59 from continuing operations excluding items.Sees FY 2017 earnings per share $2.40 to $2.43 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.85 to $1.93.Baxter International Inc - ‍qtrly sales within U.S. were approximately $1.1 billion, advancing 8 percent​.Baxter International - Sees Q4 revenue to be negatively impacted by about $70 million due to temporary manufacturing disruptions resulting from Hurricane Maria​.Baxter - Qtrly ‍international sales about $1.6 billion, representing a 5 percent increase on reported basis and a 4 percent increase on a constant currency basis​.Baxter International - ‍For FY 2017, co now expects sales growth of about 4 percent on a reported basis, about 4 percent on a constant currency basis​.Q3 adjusted earnings per share $0.64 from continuing operations excluding items.Baxter International Inc - ‍Remains in limited production across all three manufacturing sites in Puerto Rico​.FY2017 earnings per share view $2.39, revenue view $10.50 billion -- Thomson Reuters I/B/E/S.  Full Article

Baxter provides update on Puerto Rico recovery status post Hurricane Maria
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Baxter International Inc :Baxter provides update on Puerto Rico recovery status post Hurricane Maria.Baxter International Inc - ‍company expects to mitigate earnings impact from Hurricane Maria​.Baxter International Inc - ‍resumed limited production at all Puerto Rico manufacturing sites​.Baxter International Inc - ‍Baxter's three Puerto Rico manufacturing sites sustained minimal structural damage from impact of Hurricane Maria​.Baxter - co granted discretion for temporary importation of some products from facilities in Ireland, Australia to support product supply for U.S. market​.Baxter International Inc - ‍company does not manufacture large volume sterile solutions, such as its 1 liter IV solutions, in Puerto Rico​.  Full Article

EXCLUSIVE-Campbell Soup steps up CEO search, COO a contender -sources

Sept 9 Campbell Soup Co's board is drawing up a list of CEO candidates, with Chief Operating Officer Luca Mignini emerging as the top internal contender, as the company seeks to fend off a proxy challenge from Daniel Loeb's hedge fund, Third Point LLC, people familiar with the matter said.